Theralase Technologies Inc.
TLT.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 751.20K | 725.30K | 680.40K | 769.70K | 792.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 751.20K | 725.30K | 680.40K | 769.70K | 792.70K |
| Cost of Revenue | 349.50K | 350.40K | 347.10K | 375.90K | 376.60K |
| Gross Profit | 401.70K | 374.90K | 333.30K | 393.80K | 416.10K |
| SG&A Expenses | 1.53M | 1.53M | 1.53M | 1.60M | 1.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.89M | 3.93M | 3.95M | 4.07M | 4.20M |
| Operating Income | -3.13M | -3.21M | -3.27M | -3.30M | -3.40M |
| Income Before Tax | -3.11M | -3.18M | -3.25M | -3.29M | -3.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.11 | -3.18 | -3.25 | -3.29 | -3.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.11M | -3.18M | -3.25M | -3.29M | -3.39M |
| EBIT | -3.13M | -3.21M | -3.27M | -3.30M | -3.40M |
| EBITDA | -3.01M | -3.08M | -3.14M | -3.16M | -3.26M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 952.39M | 922.37M | 905.57M | 890.18M | 877.22M |
| Average Diluted Shares Outstanding | 952.39M | 922.37M | 905.57M | 890.18M | 877.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
